Literature DB >> 17292937

Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway.

Philippe Georgel1, Zhengfan Jiang, Stefan Kunz, Edith Janssen, Johann Mols, Kasper Hoebe, Siamak Bahram, Michael B A Oldstone, Bruce Beutler.   

Abstract

We have previously shown that mutations of CD14 or TLR4 impair type I interferon (IFN) production and macrophage survival during infection with vesicular stomatitis virus (VSV). We now report that VSV glycoprotein G (gpG) is essential for the induction of a previously unrecognized CD14/TLR4-dependent response pathway in which the adapter TRAM has predominant importance, absent any need for MyD88 or Mal, and with only a partial requirement for TRIF. Downstream of TRAM, IRF7 activation leads to a type I IFN response. The pathway is utilized by myeloid dendritic cells (mDCs) and macrophages rather than plasmacytoid DCs. This new mode of TLR4 signal transduction, which does not stimulate NF-kappaB activation, reveals the importance of viral protein recognition by mDCs and shows that TLR4 can drive qualitatively different events within the cell in response to different ligands.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17292937     DOI: 10.1016/j.virol.2006.12.032

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  97 in total

Review 1.  Regulation of B-cell responses by Toll-like receptors.

Authors:  Edward P Browne
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

Review 2.  When autophagy meets viruses: a double-edged sword with functions in defense and offense.

Authors:  Hee Jin Kim; Stacy Lee; Jae U Jung
Journal:  Semin Immunopathol       Date:  2010-09-25       Impact factor: 9.623

Review 3.  Accessory molecules for Toll-like receptors and their function.

Authors:  Clarissa C Lee; Ana M Avalos; Hidde L Ploegh
Journal:  Nat Rev Immunol       Date:  2012-02-03       Impact factor: 53.106

4.  Phosphoryl moieties of lipid A from Neisseria meningitidis and N. gonorrhoeae lipooligosaccharides play an important role in activation of both MyD88- and TRIF-dependent TLR4-MD-2 signaling pathways.

Authors:  Mingfeng Liu; Constance M John; Gary A Jarvis
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

Review 5.  A calculated response: control of inflammation by the innate immune system.

Authors:  Gregory M Barton
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

6.  Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions.

Authors:  Julianne Stack; Andrew G Bowie
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

7.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

8.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction.

Authors:  Kevin S Bonham; Megan H Orzalli; Kachiko Hayashi; Amaya I Wolf; Christoph Glanemann; Wolfgang Weninger; Akiko Iwasaki; David M Knipe; Jonathan C Kagan
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

Review 10.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.